Sales worse than feared, but isolated to Q1 conditions Clinical and commercial progress bodes well for mid-term Reiterate our fair value range of SEK 8-21 per share
Sales 4% higher than expected, but EBIT 4% below Weak electives in Q1’22, pushing volumes back Trading below our fair value range of SEK 8-21 per share